Search Results - "Fracasso, P. M."

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852) by Thaker, P.H., Salani, R., Brady, W.E., Lankes, H.A., Cohn, D.E., Mutch, D.G., Mannel, R.S., Bell-McGuinn, K.M., Di Silvestro, P.A., Jelovac, D., Carter, J.S., Duan, W., Resnick, K.E., Dizon, D.S., Aghajanian, C., Fracasso, P.M.

“…Preclinical studies demonstrate poly(ADP-ribose) polymerase (PARP) inhibition augments apoptotic response and sensitizes cervical cancer cells to the effects…”
Get full text

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar by FRACASSO, P. M, BLUM, K. A, DENES, A, MORTIMER, J. E, RATNER, L, IVY, S. P, MCLEOD, H. L, MA, M. K, TAN, B. R, WRIGHT, L. P, GOODNER, S. A, FEARS, C. L, HOU, W, ARQUETTE, M. A, PICUS, J

“…Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In…”
Get full text

Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies by Tan, B.R., Brenner, W.S., Picus, J., Marsh, S., Gao, F., Fournier, C., Fracasso, P.M., James, J., Yen-Revollo, J.L., Mcleod, H.L.

“…Oxaliplatin, gemcitabine and capecitabine are all active agents against upper gastrointestinal and pancreaticobiliary cancers. Patients with upper…”
Get full text

Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study by FRACASSO, Paula M, BRADY, Mark F, MOORE, David H, WALKER, Joan L, ROSE, Peter G, LETVAK, Laurie, GROGAN, Thomas M, MCGUIRE, William P

“…A phase II study was conducted to determine the efficacy of paclitaxel and valspodar (PSC 833) in patients with advanced epithelial ovarian cancer. Valspodar,…”
Get full text

Modulation of the Multidrug Resistance P-Glycoprotein: Detection with Technetium-99m-Sestamibi In Vivo by Luker, Gary D, Fracasso, Paula M, Dobkin, Jeffrey, Piwnica-Worms, David

“…Overexpression of the multidrug resistance (MDR1) P-glycoprotein (Pgp) has been documented in nearly all forms of human cancers and increased levels of Pgp in…”
Get full text

Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies by FRACASSO, P. M, WESTERVELDT, P, FEARS, C. A, ROSEN, D. M, ZUHOWSKI, E. G, CAZENAVE, L. A, LITCHMAN, M, EGORIN, M. J

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of paclitaxel when given with PSC 833 (valspodar) to patients…”
Get full text

Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group Study by FLEMING, Gini F, FOWLER, Jeffrey M, MCGUIRE, William P, WAGGONER, Steven E, COPELAND, Larry J, GREER, Benjamin E, HOROWITZ, Ira, SUTTON, Gregory, SCHILDER, Russell J, FRACASSO, Paula M, BALL, Harrison G

“…The primary objective of this phase I trial was to determine the feasibility of administering a combination of paclitaxel, cisplatin, and doxorubicin with or…”
Get full text

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies by Fracasso, P. M., Rader, J. S., Govindan, R., Herzog, T. J., Arquette, M. A., Denes, A., Mutch, D. G., Picus, J., Tan, B. R., Fears, C. L., Goodner, S. A., Sun, S. L.

“…Background: Rubitecan (9-nitrocamptothecin, 9-NC, Orathecin™) and gemcitabine have single-agent activity in pancreatic and ovarian carcinoma. We conducted a…”
Get full text

Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells by SLAPAK, C. A, FRACASSO, P. M, MARTELL, R. L, TOPPMEYER, D. L, LECERF, J.-M, LEVY, S. B

“…Multidrug-resistant sublines of the murine erythroleukemia cell line PC4 were sequentially selected in increasing vincristine concentrations (5-160 ng/ml). The…”
Get full text

Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma by Fracasso, P M, Tan, Jr, B R, Grieff, M, Stephenson, Jr, J, Liapis, H, Umbeck, N L, Von Hoff, D D, Rowinsky, E K

“…Francasso et al report a case of membranoproliferative glomerulonephritis (MPGN) in a patient with peritoneal mesothelioma who responded to treatment with…”
Get full text

HPLC method for monitoring SDZ PSC 833 in whole blood by Scott, Mitchell G, Hock, Karl G, Crimmins, Daniel L, Fracasso, Paula M

“…P-glycoprotein (Pgp) is a 170-kDa membrane transporter that mediates drug efflux and is an effector of multidrug resistance. SDZ PSC 833 (PSC), a…”
Get full text

Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells by FRACASSO, P. M, SARTOLLI, A. C

“…Solid neoplasms may contain deficient or poorly functional vascular beds, a property that leads to the formation of hypoxic tumor cells, which form a…”
Get full text

Overcoming drug resistance in ovarian carcinoma by Fracasso, P M

“…Advanced epithelial ovarian carcinoma is treated with cytoreductive surgery and combination chemotherapy with a platinum compound and paclitaxel. Despite this…”
Get full text

Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma by Perez, C A, Fields, J N, Fracasso, P M, Philpott, G, Soares, Jr, R L, Taylor, M E, Lockett, M A, Rush, C

“…Inflammatory carcinoma of the breast has been associated with a poor prognosis. Several therapeutic approaches have been under investigation in an effort to…”
Get more information

The Goldmeier effect in adults and children: environmental, retinal, and phenomenal influences on judgments of visual symmetry by Fisher, C B, Fracasso, M P

“…Adults judge that patterns symmetrical about the vertical axis are more similar to standard patterns symmetrical about both major orthogonal axes than are…”
Get more information

Differential changes in genome structure and expression of the mdr gene family in multidrug-resistant murine erythroleukemia cell lines by Fracasso, P M, Slapak, C A, Nair, S, Modrak, D, Draper, M P, LeCerf, J M, Levy, S B

“…The genome structure and expression of mdr genes were examined in multidrug-resistant sublines of two different murine (DBA/2J) Friend erythroleukemia cell…”
Get more information

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies by Fracasso, Paula M., Rodriguez, Luis C., Herzog, Thomas J., Fears, Carole L., Goodner, Sherry A., Govindan, Ramaswamy, Picus, Joel, Rader, Janet S., Tan, Benjamin R., Arquette, Matthew A.

“…BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to…”
Get full text

Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors by PATNAIK, Amita, WARNER, Ellen, OZA, Amit M, MICHAEL, Michael, EGORIN, Merrill J, MOORE, Malcolm J, SIU, Lillian L, FRACASSO, Paula M, RIVKIN, Saul, KERR, Ian, LITCHMAN, Manuel

“…To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered…”
Get full text

A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy by Chu, Q.S.-C., Markman, B., Leighl, N., Krug, L., Rudin, C., Lathers, D., Basciano, P., Fracasso, P.M., Kollia, G., Phillips, P., Kolaitis, G., Williams, D., Jackson, J., Ready, N.

Get full text

A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung) by Fracasso, P.M., Freeman, D.J., Simonsen, K., Shen, Y., Gupta, M., Comprelli, A., Gainor, J.F., Hellmann, M., Chow, L.Q., Forde, P.M., Govindan, R., Reilly, T.P., Cassidy, J.

Get full text